

5. References

1. Cancer Information Service NCCJ. Cancer Registry and Statistics [Internet]. [cited 2024 Jan 24]. Available from: https://ganjoho.jp/reg_stat/index.html
2. Sekiguchi M, Igarashi A, Sakamoto T, Saito Y, Esaki M, Matsuda T. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score. *Journal of Gastroenterology and Hepatology (Australia)*. 2020 Sep 1;35(9):1555–61.
3. National Cancer Institute. Cancer Trends Progress Report [Internet]. [cited 2024 Jan 24]. Available from: https://progressreport.cancer.gov/detection/colorectal_cancer
4. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. *New England Journal of Medicine*. 2014 Apr 3;370(14):1287–97.
5. Peterse EFP, Meester RGS, De Jonge L, Omidvari AH, Alarid-Escudero F, Knudsen AB, et al. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests. *J Natl Cancer Inst*. 2021 Feb 1;113(2):154–61.
6. Ladabaum U, Mannalithara A. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia. *Gastroenterology*. 2016 Sep 1;151(3):427-439.e6.
7. Sekiguchi M, Igarashi A, Matsuda T, Matsumoto M, Sakamoto T, Nakajima T, et al. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: A cost-effectiveness analysis using Japanese data. *Jpn J Clin Oncol*. 2016 Feb 1;46(2):116–25.
8. Saito Y, Oka S, Kawamura T, Shimoda R, Sekiguchi M, Tamai N, et al. Colonoscopy screening and surveillance guidelines. Vol. 33, *Digestive Endoscopy*. John Wiley and

- Sons Inc; 2021. p. 486–519.
9. Ministry of Health L and W. Action against cancer promotion master plan (the 4th period) [Internet]. 2023 [cited 2024 Jan 24]. Available from: https://www.mhlw.go.jp/stf/newpage_32248.html
 10. Weiser E, Parks PD, Swartz RK, Thomme J Van, Lavin PT, Limburg P, et al. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: Real-world data from a large cohort of older adults. *J Med Screen*. 2020;
 11. Ioannou S, Sutherland K, Sussman DA, Deshpande AR. Increasing uptake of colon cancer screening in a medically underserved population with the addition of blood-based testing. *BMC Cancer*. 2021 Dec 1;21(1).
 12. Goede SL, Van Roon AHC, Reijerink JCIY, Van Vuuren AJ, Lansdorp-Vogelaar I, Habbema JDF, et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. *Gut*. 2013 May;62(5):727–34.
 13. Sweet A, Lee D, Gairy K, Phiri D, Reason T, Lock K. The Impact of CT Colonography for Colorectal Cancer Screening on the UK NHS Costs, Healthcare Resources and Health Outcomes. *Appl Health Econ Health Policy* [Internet]. 2011;9(1):51–64. Available from: <http://links.adisonline>.
 14. Matsuda T, Fujii T, Sano Y, Kudo SE, Oda Y, Hotta K, et al. Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy: The Japan Polyp Study Workgroup. *Gut*. 2021 Aug 1;70(8):1469–78.
 15. Japan Society for Cancer of the Colon and Rectum. Multi-institutional registry of large bowel cancer in Japan Vol. 40 cases treated in 2014 [Internet]. 2023 [cited 2024 Jan 24]. Available from: https://jsccr.jp/registration/pdf/Vol_40.pdf
 16. Ministry of Health L and W. Vital statistics of population [Internet]. 2017 [cited 2024

- Jan 24]. Available from:
<https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei17/index.html>
17. Cancer Information Service NCCJ. Cancer Statistics (Vital Statistics of Japan, Ministry of Health, Labour and Welfare) [Internet]. [cited 2024 Jan 24]. Available from:
https://ganjoho.jp/reg_stat/statistics/data/dl/index.html
 18. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Sakaguchi K, et al. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas. *American Journal of Gastroenterology*. 2007 Oct;102(10):2259–64.
 19. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A Comparison of the Immunochemical Fecal Occult Blood Test and Total Colonoscopy in the Asymptomatic Population. *Gastroenterology*. 2005 Aug;129(2):422–8.
 20. Potter NT, Hurban P, White MN, Whitlock KD, Lofton-Day CE, Tetzner R, et al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. *Clin Chem*. 2014;60(9):1183–91.
 21. Furuta T, Kato M, Ito T, Inaba T, Komura N, Katanuma A. 6th Report of endoscopic complications: Results of the Japan Gastroenterological Endoscopy Society Survey from 2008 to 2012. *Gastroenterological Endoscopy*. 2016;58:1466–91.
 22. Center for Outcomes Research and Economic Evaluation for Health NI of PH (C2H). Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council [Internet]. 2022 [cited 2024 Jan 21]. Available from:
https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf
 23. Hasegawa M, Komoto S, Shirowa T, Fukuda T. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System. *Value in Health*. 2020 Jan 1;23(1):43–51.
 24. Jahn B, Sroczynski G, Bundo M, Mühlberger N, Puntcher S, Todorovic J, et al.

- Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria. *BMC Gastroenterol.* 2019 Dec 5;19(1).
25. Kamba S, Tamai N, Saitoh I, Matsui H, Horiuchi H, Kobayashi M, et al. Reducing adenoma miss rate of colonoscopy assisted by artificial intelligence: a multicenter randomized controlled trial. *J Gastroenterol.* 2021 Aug 1;56(8):746–57.
 26. The Japanese Society of Gastroenterology. Evidence-based Clinical Practice Guidelines for Colonic Polyp 2020 (2nd Edition). 2020.
 27. Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J. Option appraisal of population-based colorectal cancer screening programmes in England. *Gut.* 2007 May;56(5):677–84.
 28. Barré S, Leleu H, Benamouzig R, Saurin JC, Vimont A, Taleb S, et al. Cost-effectiveness analysis of alternative colon cancer screening strategies in the context of the French national screening program. *Therap Adv Gastroenterol.* 2020;13.
 29. Subramanian S, Tangka FKL, Hoover S, DeGroff A, Royalty J, Seeff LC. Clinical and programmatic costs of implementing colorectal cancer screening: Evaluation of five programs. *Eval Program Plann.* 2011 May 1;34(2):147–53.
 30. Redwood DG, Dinh TA, Kisiel JB, Borah BJ, Moriarty JP, Provost EM, et al. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People. *Mayo Clin Proc.* 2021 May 1;96(5):1203–17.
 31. Ladabaum U, Allen J, Wandell M, Ramsey S. Colorectal cancer screening with blood-based biomarkers: Cost-effectiveness of methylated septin 9 DNA versus current strategies. *Cancer Epidemiology Biomarkers and Prevention.* 2013 Sep;22(9):1567–76.
 32. Ladabaum U, Alvarez-Osorio L, Rösch T, Brueggenjuergen B. Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies

- versus plasma methylated Septin 9 DNA. *Endosc Int Open*. 2014 Jun 6;02(02):E96–104.
33. Lew J Bin, St. John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, et al. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. *Int J Cancer*. 2018 Jul 15;143(2):269–82.
 34. Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. *Gut*. 2014 Feb;63(2):317–25.
 35. Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: Review and recommendations from an expert panel. Vol. 107, *American Journal of Gastroenterology*. 2012. p. 1315–29.
 36. Ministry of Health L and W. Consultation rate improvement policy handbook (the 3rd edition) [Internet]. [cited 2024 Jan 24]. Available from:
<https://www.mhlw.go.jp/content/10900000/001109465.pdf>
 37. Ministry of Health L and W. Consultation rate improvement policy handbook (the 2nd edition) [Internet]. [cited 2024 Jan 24]. Available from:
<https://www.mhlw.go.jp/content/10901000/000500406.pdf>